BTK and systemic lupus erythematosus: BCR function is also regulated by FcγRIIB, which increases the threshold for B-cell activation [29], and Bruton’s tyrosine kinase (BTK), whose inhibition has improved the manifestations of autoimmune diseases in studies on arthritis and lupus mouse models, suggesting that BTK might be a therapeutic target in SLE [30].